共 50 条
- [41] EFFICACY OF RISANKIZUMAB RESCUE THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE CROHN'S DISEASE AND INADEQUATE RESPONSE TO RISANKIZUMAB MAINTENANCE THERAPYGASTROENTEROLOGY, 2022, 162 (07) : S967 - S967Baert, Filip J.Atreya, RajaKakuta, YoichiLong, Millie D.Roblin, XavierNeimark, EzequielSong, Alexandra P.Wallace, KoriKligys, KristinaMallick, MadhujaLiao, XiaomeiLim, Allen
- [42] THE EFFICACY AND SAFETY OF GUSELKUMAB INDUCTION THERAPY IN PATIENTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS FROM THE PHASE 3 QUASAR INDUCTION STUDYGASTROENTEROLOGY, 2023, 164 (06) : S1572 - S1572Allegretti, Jessica R.Peyrin-Biroulet, LaurentFeagan, Brian G.Bressler, BrianLichtenstein, Gary R.Huang, Kuan-Hsiang G.Germinaro, MatthewShipitofsky, NicoleJiang, LingjingZhang, HongyanHisamatsu, TadakazuPanes, JulianDignass, AxelSands, Bruce E.Rubin, David T.
- [43] Efficacy of Induction upadacitinib Therapy in Chinese Patients with Moderately to Severely Active Crohn's DiseaseJOURNAL OF CROHNS & COLITIS, 2024, 18 : I1213 - I1213Chen, M.Gao, X.Cao, Q.Zhang, X.Chen, Y.Hou, X.Zhong, J.Sun, Y.Phaleng, X.
- [44] Efficacy and Safety of Upadacitinib Induction Therapy in Patients With Moderately to Severely Active Crohn's Disease: Results From a Randomized Phase 3 U-EXCEL StudyAMERICAN JOURNAL OF GASTROENTEROLOGY, 2022, 117 (10): : S518 - S518Loftus, Edward V.Colombel, Jean-FredericLacerda, Ana PaulaPeyrin-Biroulet, LaurentD'Haens, GeertPanaccione, RemoReinisch, WalterLouis, EdouardChen, MinhuNakase, HiroshiGreenbloom, SusanDuVall, GeorgeSanchez-Gonzalez, YuriMohamed, Mohamed-EslamRhee, SusanFeng, TianDubcenco, ElenaPanes, Julian
- [45] Efficacy and safety of vedolizumab subcutaneous formulation in patients with moderately to severely active Crohn's disease: Results of the VISIBLE 2 studyJOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2020, 35 : 115 - 115Vermeire, S.Sandborn, W.Danese, S.Baert, F.Kobayashi, T.Loftus, E.Bhatia, S.Kisfalvi, K.Rosario, M.Zhang, W.D'Haens, G.
- [46] The Safety and Efficacy of Induction and Maintenance Therapy with Infliximab in Children with Severely Active Crohn's DiseaseAMERICAN JOURNAL OF GASTROENTEROLOGY, 2009, 104 : S469 - S469Kierkus, JaroslawDadalski, MaciejRyzko, JozefSocha, PiotrOracz, GrzegorzSzczepanski, MichalSzymanska, EdytaSocha, Jerzy
- [47] Efficacy of subcutaneous guselkumab induction therapy by baseline demographics and concomitant medications in participants with moderately to severely active Crohn's disease: Results from the phase 3 GRAVITI studyJOURNAL OF CROHNS & COLITIS, 2025, 19 : i1312 - i1314Hart, A.Hisamatsu, T.Steinwurz, F.D'Haens, G.Liu, W.Olurinde, M.Ngqawa, P.Yang, Z.Merrall, E.Terry, N. A.Panaccione, R.Sands, B. E.
- [48] EFFICACY AND SAFETY OF COMBINATION INDUCTION THERAPY WITH GUSELKUMAB AND GOLIMUMAB IN PATIENTS WITH MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: RESULTS THROUGH WEEK 12 OF THE PHASE 2A VEGA STUDYGASTROENTEROLOGY, 2022, 162 (07) : S215 - S216Feagan, Brian G.Sands, Bruce E.Sandborn, William J.Shipitofsky, NicoleMarko, Melissa G.Sheng, ShihongJohanns, JewelGerminaro, MatthewVetter, MarionPanes, Julian
- [49] Mirikizumab Sustained Improvement on Fatigue in Patients With Moderately to Severely Active Crohn's Disease in the Phase 2 AMAG Study at Week 104AMERICAN JOURNAL OF GASTROENTEROLOGY, 2023, 118 (10): : S816 - S816Regueiro, MiguelFischer, MonikaBossuyt, PeterMcGinnis, KimGibble, Theresa HunterProtic, MarijanaPanni, TommasoHibi, ToshifumiRubin, David T.
- [50] Comparison of pharmacodynamic and mechanistic response of guselkumab intravenous and subcutaneous induction in moderately to severely active Crohn's disease: molecular analysis of the GRAVITI and GALAXI Phase 3 studiesJOURNAL OF CROHNS & COLITIS, 2025, 19 : i600 - i601Richards, D.Patel, R.Sohn, K.Hart, A.Lee, T.Liu, J.Sisk, C.Olurinde, M.Terry, N.Mcrae, B.Reinisch, W.Feagan, B.Steinwurz, F.Panaccione, R.D'Haens, G.Branigan, P.